Rush.cloud

Rush is an AI-powered drug discovery platform built to augment the work of scientists through machine-driven superintelligence. The platform combines machine learning, computational chemistry, and large language models to make state-of-the-art drug discovery tools accessible to researchers who may not have a computational background. Rush's core mission is to rethink the drug discovery process for the age of artificial intelligence, ultimately enabling what the company describes as the "1000x drug hunter" — a researcher empowered by intelligent systems that can plan, execute, and reason about complex scientific programs in collaboration with human scientists.

Rush serves individual scientists, lean biotech startups, and large enterprise organizations alike. For researchers and medicinal chemists, the platform unlocks capabilities that were previously inaccessible without specialist expertise. For startups, it provides expert-level methods across disciplines without requiring a large team. For enterprises, Rush offers unified access to cutting-edge capabilities across an organization, breaking down silos and streamlining collaboration at scale. Early adopters include academic institutions such as Monash Institute of Pharmaceutical Sciences and Chulalongkorn University, as well as commercial partners including Chemspace and biotech startup Imitex.

Hit Finding and Evaluation Modules

• Structure Prediction: Predicts the 3D structure of biological molecules and their interactions, including protein folding, protein-protein, protein-peptide, and protein-ligand complexes.
• Binding Site Prediction: Identifies potential ligand-binding pockets on a protein surface using structure-based computational methods.
• Virtual Screening: Rapidly and cost-effectively evaluates hundreds of thousands of compounds against a biological target using computational models, enabling hit identification before any laboratory testing is required.
• Molecular Docking: Predicts how a molecule fits and interacts within a protein's binding site, revealing potential binding strength and orientation.
• Super Accurate Binding Affinity: Leverages quantum mechanical calculations to precisely estimate binding strength between a molecule and its target, improving hit prioritization and lead selection.

Activity Understanding and Prediction Modules

• Patent SAR Extraction: Automatically mines patents and scientific papers for structure-activity relationship (SAR) data, converting buried chemical insights into structured, searchable knowledge.
• SAR Analysis: Analyzes SAR data to uncover trends between chemical structure and biological activity, guiding lead optimization efforts.
• QSAR, Property Prediction, and Optimisation: Uses quantitative structure-activity relationship models to forecast how structural changes influence a molecule's activity, and predicts key properties to guide optimization for potency, safety, and drug-likeness.
• QM/MM Simulation: Combines quantum mechanics and molecular mechanics to accurately model chemical reactions or binding events at an atomic level within complex biological systems.

New Chemistry Design Modules

• Small Molecule Generation: Explores chemical space by generating novel compounds structurally similar to a chosen reference molecule.
• Small Molecule Similarity Search: Finds purchasable compounds with similar structures to a reference compound, uncovering potential analogs for further investigation.
• Automated Bioisostere Enumeration: Systematically swaps parts of a molecule with known bioisosteric replacements, generating smart analogs that maintain activity while exploring new chemical space and potentially improving potency, selectivity, or drug-like properties.

Platform Context and Market Problem

• For every 20 life science researchers, there is only one computational chemist — creating a significant bottleneck in modern drug discovery programs.
• State-of-the-art drug discovery software can cost millions of dollars over the lifetime of a full drug discovery program, making it inaccessible to many teams.
• The life sciences field generates over one million new publications per year, two million crystallized structures, and encompasses more than 20,000 software tools — creating an overwhelming volume of information for scientists to navigate.
• Rush addresses these challenges by providing accessible, AI-assisted tools with commercial terms designed to work for organizations of all sizes, including early-stage startups spun out of research institutions.

Product Roadmap and Vision

• Phase 1: Make computational tools accessible to non-computational scientists, support researchers with large language models customized for drug discovery, and automatically deliver actionable insights for medicinal chemists.
• Phase 2: Deploy specialized artificial intelligences to solve increasingly complex problems by planning and executing custom in silico workflows, reasoning about results, adjusting to new data, and making recommendations.
• Phase 3: Integrate with physical chemistry and biology laboratories so that planning and execution can extend beyond software to include real-world experiments and data gathering.
• Phase 4: Enable artificial intelligence to augment every part of the process of designing, making, and testing new drug candidates.

Rush is positioned as a foundational platform for both academic and commercial drug discovery, with integrations including Chemspace's virtual compound libraries. The platform is designed to eliminate friction in scientific workflows, empowering scientists at every level to make smarter, faster decisions and accelerate the path from idea to impact.